APG vs ATI

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong recent price performance and robust revenue and earnings growth, the stock trades at a steep valuation (P/E of 116.19 vs. sector average of 48.97) far above its Graham Number of $7.99 and intrinsic value of $10.62, suggesting significant overvaluation. Earnings quality is deteriorating, with 3 of the last 4 quarters missing estimates by an average of -32.33%, and YoY EPS has declined by 41.2% despite positive Q/Q growth. Heavy insider selling of $20.69M in the last 6 months and a bearish technical trend further reinforce caution.

ATI has a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm solvency. Despite strong recent earnings growth (YoY EPS +41.7%) and solid ROE of 24.62%, the stock trades at a steep valuation (P/E 39.85, Price/Book 9.83) well above the Graham Number of $29.6, suggesting significant growth expectations are already priced in. Insider selling activity worth $20.38M over the past six months signals caution, while analysts maintain a strong_buy consensus with a $133.00 target. The combination of rich multiples, weak financial health signals, and negative insider sentiment offsets strong profitability and growth metrics, resulting in a neutral outlook.